Monoclonal Antibody vs ADC — Oncology Deal Terms Comparison
Market Analysis
In oncology, Monoclonal Antibody and ADC represent two of the most actively transacted modalities. At Phase 2, Monoclonal Antibody deals carry a median total deal value of $1.7B with $266M upfront, compared to $2.6B total value and $411M upfront for ADC. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Monoclonal Antibody development milestones average $355M versus $550M for ADC. Commercial milestones are $497M for Monoclonal Antibody and $770M for ADC. Royalty rates range from 11.9%-19.5% for Monoclonal Antibody and 13.6%-22.2% for ADC.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Monoclonal Antibody and ADC deal terms compare in oncology?
Which modality commands higher royalty rates: Monoclonal Antibody or ADC?
How do milestone structures differ between Monoclonal Antibody and ADC?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.